Skip to main content

Boundless Bio to Present at the Guggenheim Oncology Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will present at the Guggenheim Oncology Conference, which will take place virtually. Presentation details are as follows:

Date: Friday, February 11, 2022

Time: 2:00 PM – 2:25 PM EST

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.79
-11.60 (-4.75%)
AAPL  297.01
-1.00 (-0.34%)
AMD  551.63
+14.26 (2.65%)
BAC  57.37
+1.17 (2.08%)
GOOG  348.78
-18.68 (-5.08%)
META  563.85
-13.37 (-2.32%)
MSFT  367.34
-12.06 (-3.18%)
NVDA  208.65
-2.04 (-0.97%)
ORCL  175.07
-9.22 (-5.00%)
TSLA  405.05
+4.56 (1.14%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.